June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Predicting Visual Outcomes in Central Retinal Vein Occlusion (CRVO) with Vascular Metrics and Non-Perfusion Area (NPA) Measured by Wide-Field Swept-Source OCT-Angiography (WF SS-OCTA)
Author Affiliations & Notes
  • Luis Antonio Martinez-Velazquez
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Grace Baldwin
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Itika Garg
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ying Cui
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Raviv Katz
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Rebecca Zeng
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Margaret Duich
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Jade Yunkyung Moon
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Filippos Vingopoulos
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Hannah Wescott
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Thomas Koch
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Nimesh A. Patel
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • David M Wu
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • John B Miller
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Luis Martinez-Velazquez None; Grace Baldwin None; Itika Garg None; Ying Cui None; Raviv Katz None; Rebecca Zeng None; Margaret Duich None; Jade Moon None; Filippos Vingopoulos None; Hannah Wescott None; Thomas Koch None; Nimesh Patel Alimera Sciences, Alcon, Allergan, and Genentech, Code C (Consultant/Contractor); David Wu D.M.W. holds a patent through Massachusetts Eye and Ear., Code P (Patent); John Miller Alcon, Allergan, Carl Zeiss, Sunovion and Genentech., Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2937 – F0090. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Luis Antonio Martinez-Velazquez, Grace Baldwin, Itika Garg, Ying Cui, Raviv Katz, Rebecca Zeng, Margaret Duich, Jade Yunkyung Moon, Filippos Vingopoulos, Hannah Wescott, Thomas Koch, Nimesh A. Patel, David M Wu, John B Miller; Predicting Visual Outcomes in Central Retinal Vein Occlusion (CRVO) with Vascular Metrics and Non-Perfusion Area (NPA) Measured by Wide-Field Swept-Source OCT-Angiography (WF SS-OCTA). Invest. Ophthalmol. Vis. Sci. 2022;63(7):2937 – F0090.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Previous studies have used optical coherence tomography angiography (OCTA) to evaluate CRVOs using smaller sized angiograms, namely 3x3 mm and 6x6 mm. We used WF SS-OCTA to quantify macular vascular metrics following CRVO and used these to model the observed visual acuity (VA).

Methods : 109 eyes of 59 patients, (59 eyes with CRVO- 9 ischemic, and 50 fellow eyes) were imaged using WF SS-OCTA (PLEX® Elite 9000, Carl Zeiss Meditec) between March 2019 and October 2021. We analyzed 12x12mm angiograms centered on the fovea using ARI Network (Zeiss Portal) Macular Density Algorithm (v0.7.3) for vessel density (VD), vessel skeleton density (VSD), foveal avascular zone (FAZ) area, circularity, and perimeter. The NPA of each macula was calculated using ImageJ. We performed mixed effects multivariate regression analyses.

Results : Our study population consisted of 33 Male (55.93%) patients with a median age of 63 years (21-86). The median logMAR visual acuity for CRVO eyes was 0.24 (20/35) vs. 0.03 (20/21) in the fellow eye (p<0.0001). CRVO eyes had larger NPAs than fellow eyes (median (m) 27.5, 7.16; Interquartile Range (IQR) 23.98, 8.47; P<0.0001), and greater irregularity of the FAZ (m 0.53, 0.79; IQR 0.25, 0.15; P=0.005). We did not detect a statistical difference in FAZ area (m 0.90, 0.27; IQR 0.29, 0.25, P=0.66) or perimeter (m 4.35, 1.23; IQR 1.88, 1.23; P=0.2).

Our regression analyses suggest that after controlling for age, ischemic CRVOs (ß= 0.35, p=0.006), larger NPAs (ß=0.007, p<0.0001), and larger FAZ area (ß= 0.048, p=0.008) were associated with worse VA. On receiver operating curve (ROC) analysis, wide-field NPA was the best OCTA metric in predicting VA worse than 20/50, area under the curve (AUC) 0.91.

Conclusions : In patients with CRVO, the WF SS-OCTA allows for quantification of NPAs in a larger region of the macula, while still providing useful information pertaining to the perifoveal vascularity. Our study reinforces prior reports that larger NPAs and larger FAZ area are associated with worse VA. WF SS-OCTA could therefore contribute to the evaluation, management, and counseling of a patient with CRVO, by identifying factors associated with worse visual outcomes following the diagnosis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×